Top 2% Biotech Flirts With Profit-Taking Zone On $145 Million Deal
Biotech company ARS Pharmaceuticals saw a surge in shares after partnering with ALK-Abello to market its nasal spray Neffy for allergic reactions globally. The deal includes a $145 million upfront payment and potential milestones and royalties, targeting a large epinephrine market.